Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the Netherlands / NCT05080569
Recruiting Phase 4

Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment

NCT05080569 · tracked via the Priya Life Science Netherlands tracker
Sponsor
UMC Utrecht
Phase
Phase 4
Started
2023-03-01
Last updated
2025-12-31

Condition(s) studied

Pregnancy RelatedFertility IssuesLuteal Phase DefectInfertility Unexplained

Investigational drug(s) / intervention(s)

Progesterone Vaginal Product →Placebo

Progesterone Vaginal Product: 3dd200mg

Placebo: 3dd1 vaginal capsule

Study summary

The LUMO study is a multicenter, randomized controlled trial that evaluates the effectivity of luteal phase support in MOH/IUI treatment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Couples starting IUI with Mild Ovarian HyperStimulation (MOH), with the intend to receive this treatment for at least six months. * Diagnosis of unexplained (primary or secondary) infertility * Hunault \<30% (or \>30%, after an expectant management period of at least 6 additional months). * Females aged \>18 years with regular menstrual cycle. * Total mobile sperm count (VCM) \>10 million. Exclusion cirteria: * Cycle irregularities * Male factor infertility

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
UMC Utrecht Utrecht Netherlands Recruiting

More UMC Utrecht trials in the Netherlands

Course of Face-to-face Interactions in Adults With Autism Recruiting
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis Recruiting
Focused Ultrasound Blood-Brain Barrier Opening in Pontine Diffuse Midline Glioma to Enhance Temozolomide Therapy: Pilot Feasibility Study (FIDES) Starting soon
Hand Function Impairment in Systemic Sclerosis: Outcomes, Mechanisms and Experience (HANDSOME) Recruiting
Use of a Putty as Gap Filler in Open-wedge Osteotomy Recruiting

Other trials for the same condition

Innovation for Small-scale Experiments: ReceptIVFity Test Recruiting
The Prospective Observational COMPRAYA Cohort Study Recruiting
Feasibility of Remote eCTG Monitoring Home@Hospital in Complicated Pregnancies Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05080569 on ClinicalTrials.gov ↗ ← All trials in the Netherlands